- Trials with a EudraCT protocol (9)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
9 result(s) found for: Tyrosinase.
Displaying page 1 of 1.
| EudraCT Number: 2009-015737-73 | Sponsor Protocol Number: 2009-015737-73 | Start Date*: 2010-02-04 |
| Sponsor Name:Radboud University Nijmegen Medical Centre | ||
| Full Title: Single-step antigen loading and TLR activation of dendritic cells by mRNA electroporation for vaccination in stage III and IV melanoma patients | ||
| Medical condition: Our study population consists of melanoma patients, with proven expression of melanoma associated tumor antigens gp100 and tyrosinase. Melanoma patients with regional lymph node metastasis in whom ... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Temporarily Halted) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2008-001973-14 | Sponsor Protocol Number: KUN2006-3699 | Start Date*: 2009-04-27 |
| Sponsor Name:Radboud University Nijmegen Medical Centre | ||
| Full Title: TLR ligand matured dendritic cell vaccination in melanoma patients: the key towards a more potent immune induction? | ||
| Medical condition: Our study population consists of HLA-A2.1 positive melanoma patients, with proven expression of melanoma associated tumor antigens gp100 and tyrosinase. Melanoma patients with regional lymph node m... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2008-001974-33 | Sponsor Protocol Number: 08/014 | Start Date*: 2009-04-14 |
| Sponsor Name:Radboud University Nijmegen Medical Centre [...] | ||
| Full Title: mRNA-transfected dendritic cell vaccination in high risk uveal melanoma patients | ||
| Medical condition: Our study population consists of HLA-A2.1 positive patients with a high risk uveal melanoma (stage II) with proven expression of melanoma associated antigens tyrosinase and/or gp100. Patients are i... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2010-020228-23 | Sponsor Protocol Number: NL32381.000.10 | Start Date*: 2010-12-21 |
| Sponsor Name:Radboud University Nijmegen Medical Centre | ||
| Full Title: Immunochemotherapy: Do platin-based chemotherapeutics enhance dendritic cell vaccine efficay in melanoma patients? | ||
| Medical condition: Our study population consists of melanoma patients, with proven expression of melanoma associated tumor antigens gp100 and tyrosinase. Melanoma patients with regional lymph node metastasis in whom ... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2006-002941-35 | Sponsor Protocol Number: PGMECON | Start Date*: 2006-07-31 | |||||||||||
| Sponsor Name:AZIENDA OSPEDALIERA S. LUIGI GONZAGA | |||||||||||||
| Full Title: EFFECTS OF PROSTAGLANDIN COMPOUNDS ON CONJUNTIVAL MELANOGENESIS: AN IMPRESSION CITOLOGY AND TYROSINASE MARKERS STUDY | |||||||||||||
| Medical condition: EVALUATION OF CONJUNTIVAL MELANOGENESIS IN HEALTHTY VOLOUNTEERS AND GLAUCOMATOUS PATIENTS IN THERAPY WITH PROSTAGLANDIN COMOUNDS | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2006-000228-14 | Sponsor Protocol Number: LUC 05-003 | Start Date*: 2006-02-21 |
| Sponsor Name:Cliniques Universitaires Saint-Luc | ||
| Full Title: Immunization of disease-free melanoma patients with different HLA-A2 peptides. | ||
| Medical condition: We want to vaccine HLA-A2 patients who had a cutaneous melanoma at the following AJCC stage T3b-T4 N0 M0, Tx N1-3 M0, Tx Nx M0. Disease-free after surgery. With no previous immunizations with the s... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2013-001132-22 | Sponsor Protocol Number: GEM-1202 | Start Date*: 2014-02-24 |
| Sponsor Name:Grupo Español Multidisciplinar de Melanoma | ||
| Full Title: A MULTICENTER, SINGLE ARM, PHASE 2 CLINICAL STUDY ON THE COMBINATION OF RADIATION THERAPY AND IPILIMUMAB, FOR THE TREATMENT OF PATIENTS WITH MELANOMA AND BRAIN METASTASES. | ||
| Medical condition: Patients with melanoma and brain metastases | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2009-015720-28 | Sponsor Protocol Number: CCRG 09-003 | Start Date*: 2009-12-18 | |||||||||||||||||||||
| Sponsor Name:Antwerp University Hospital | |||||||||||||||||||||||
| Full Title: Therapeutic efficacy of Wilms tumor gene (WT1) mRNA-electroporated autologous dendritic cell vaccination in patients with myeloid malignancies and multiple myeloma: a phase II trial. | |||||||||||||||||||||||
| Medical condition: Therapeutic vaccination with dendritic cells loaded with wilms' tumor 1 protein in patients with myeloid malignancies and multiple myeloma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: BE (Completed) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2020-002195-12 | Sponsor Protocol Number: BNT111-01 | Start Date*: 2021-04-27 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:BioNTech SE | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: An open-label, randomized Phase II trial with BNT111 and cemiplimab in combination or as single agents in patients with anti-PD1-/ PD-L1-refractory/relapsed, unresectable Stage III or IV melanoma | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Anti-PD1-/ PD-L1-refractory/relapsed, unresectable Stage III or IV melanoma | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
